‘Fasenra,’ a severe asthma treatment, has been listed for insurance reimbursement this month and is now available for prescriptions at general hospitals.

Industry sources said that AstraZeneca Korea’s Fasenra (benralizumab) has passed the drug committees (DC) of tertiary general hospitals, including Samsung Medical Center in Seoul, Seoul National University, Seoul Asan Hospital, and Seoul St. Mary’s Hospital, and medical institutions, including Kyungpook National University Hospital, Pusan National University Hospital, Seoul National University Bundang Hospital, Ajou University Hospital, Chonnam National University Hospital, and Chungnam National University Hospital.

Since July 1st,